Accession Therapeutics Limited
Nicola B. has a diverse work experience in the scientific field. They started their career in 2008 as a Cell Biologist at Prosidion Ltd. They then worked as an Analytical Scientist at Syntaxin Ltd An Ipsen Company before moving to UCB as a Senior Analytical Scientist in 2008. In 2014, Nicola joined Immunocore as a Senior Analytical Development Scientist and later transitioned to the role of Principal Scientist in Analytical Development, CMC. Most recently, in 2022, Nicola joined Accession Therapeutics Limited as a Principal Scientist in Analytical Development, CMC.
Nicola B. has a Bachelor of Science (BSc) degree in Biomedical Sciences, General from the University of Bradford. They also hold a Doctor of Philosophy (Ph.D.) degree in Biochemistry from the University of Sussex.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.